BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchesini G, Marzocchi R. Metabolic Syndrome and NASH. Clin Liver Dis. 2007;11:105-117, ix. [PMID: 17544974 DOI: 10.1016/j.cld.2007.02.013] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Nobili V, Alisi A, de Ville de Goyet J. Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children. Liver Transpl 2011;17:620-1. [PMID: 21351243 DOI: 10.1002/lt.22285] [Reference Citation Analysis]
2 de la Monte SM, Neusner A, Chu J, Lawton M. Epidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer’s disease, diabetes mellitus, and non-alcoholic steatohepatitis. J Alzheimers Dis. 2009;17:519-529. [PMID: 19363256 DOI: 10.3233/jad-2009-1070] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
3 Zhang DD, Zhang JG, Wang YZ, Liu Y, Liu GL, Li XY. Per-Arnt-Sim Kinase (PASK): An Emerging Regulator of Mammalian Glucose and Lipid Metabolism. Nutrients 2015;7:7437-50. [PMID: 26371032 DOI: 10.3390/nu7095347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
4 Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol Res 2018;134:257-67. [PMID: 29964161 DOI: 10.1016/j.phrs.2018.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
5 Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015;52:117-123. [PMID: 26039829 DOI: 10.1590/s0004-28032015000200008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
6 Yilmaz Y. Cytokeratins in hepatitis. Clin Chim Acta 2011;412:2031-6. [PMID: 21925155 DOI: 10.1016/j.cca.2011.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
7 Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol 2012; 18(13): 1508-1516 [PMID: 22509083 DOI: 10.3748/wjg.v18.i13.1508] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
8 Li Y, Lu Z, Zhang L, Kirkwood CL, Kirkwood KL, Lopes-Virella MF, Huang Y. Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss. J Periodontal Res 2021. [PMID: 34748647 DOI: 10.1111/jre.12951] [Reference Citation Analysis]
9 de la Monte SM, Wands JR. Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed. J Diabetes Sci Technol 2008;2:1101-13. [DOI: 10.1177/193229680800200619] [Cited by in Crossref: 576] [Cited by in F6Publishing: 519] [Article Influence: 44.3] [Reference Citation Analysis]
10 Noh J. Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr 2020;29:1-3. [PMID: 32182638 DOI: 10.7570/jomes20017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Tian YF, He CT, Chen YT, Hsieh PS. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World J Gastroenterol 2013; 19(18): 2761-2771 [PMID: 23687413 DOI: 10.3748/wjg.v19.i18.2761] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
13 So WZ, Tan FL, Tan DJH, Ng CH, Yong JN, Syn N, Tang ASP, Wong RC, Lin W, Tan EXX, Huang DQ, Dan YY, Chew NWS, Siddiqui MS, Muthiah MD. A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. Dig Liver Dis 2021:S1590-8658(21)00851-3. [PMID: 34896025 DOI: 10.1016/j.dld.2021.11.011] [Reference Citation Analysis]
14 VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, Terrault NA, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int 2018;38:2069-81. [PMID: 29608255 DOI: 10.1111/liv.13747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metab 2018;27:339-350.e3. [PMID: 29414684 DOI: 10.1016/j.cmet.2018.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
16 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 346] [Article Influence: 53.0] [Reference Citation Analysis]
18 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
19 Heo NJ, Park HE, Yoon JW, Kwak MS, Yang JI, Chung SJ, Yim JY, Chung GE. The Association between Vitamin D and Nonalcoholic Fatty Liver Disease Assessed by Controlled Attenuation Parameter. J Clin Med 2021;10:2611. [PMID: 34199258 DOI: 10.3390/jcm10122611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vassallo P, Driver SL, Stone NJ. Metabolic Syndrome: An Evolving Clinical Construct. Prog Cardiovasc Dis 2016;59:172-7. [PMID: 27497505 DOI: 10.1016/j.pcad.2016.07.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
21 Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Intern Med 2018;57:1533-42. [PMID: 29321441 DOI: 10.2169/internalmedicine.9857-17] [Reference Citation Analysis]
22 Zhao W, Liu L, Wang Y, Mao T, Li J. Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med 2016;11:183-90. [PMID: 26889237 DOI: 10.3892/etm.2015.2846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
23 Morita Y, Senokuchi T, Yamada S, Wada T, Furusho T, Matsumura T, Ishii N, Nishida S, Nishida S, Motoshima H, Komohara Y, Yamagata K, Araki E. Impact of tissue macrophage proliferation on peripheral and systemic insulin resistance in obese mice with diabetes. BMJ Open Diabetes Res Care 2020;8:e001578. [PMID: 33087339 DOI: 10.1136/bmjdrc-2020-001578] [Reference Citation Analysis]
24 Ku CS, Yang Y, Park Y, Lee J. Health benefits of blue-green algae: prevention of cardiovascular disease and nonalcoholic fatty liver disease. J Med Food 2013;16:103-11. [PMID: 23402636 DOI: 10.1089/jmf.2012.2468] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
25 Han AL. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis. BMC Endocr Disord 2021;21:91. [PMID: 33933056 DOI: 10.1186/s12902-021-00758-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
27 Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009;14:1459-71. [PMID: 19544096 DOI: 10.1007/s10495-009-0366-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
28 Michopoulos S, Chouzouri VI, Manios ED, Grapsa E, Antoniou Z, Papadimitriou CA, Zakopoulos N, Dimopoulos AM. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center. Clin Exp Gastroenterol 2016;9:1-9. [PMID: 26834493 DOI: 10.2147/CEG.S92714] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Purnak T, Beyazit Y, Ozaslan E, Efe C, Hayretci M. The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease. Wien Klin Wochenschr. 2012;124:526-531. [PMID: 22850810 DOI: 10.1007/s00508-012-0211-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
30 Celikbilek M, Gürsoy S, Deniz K, Karaman A, Zararsiz G, Yurci A. Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease. Platelets. 2013;24:194-199. [PMID: 22646469 DOI: 10.3109/09537104.2012.688898] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
31 Xie TH, Li JX, Mao TY, Guo Y, Chen C, Han YF, Tan X, Chen RH. An ErChen and YinChen Decoction Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis in Rats by Regulating JNK1 Signaling Pathway. Evid Based Complement Alternat Med 2017;2017:4603701. [PMID: 28680450 DOI: 10.1155/2017/4603701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ercin CN, Dogru T, Tapan S, Karslioglu Y, Haymana C, Kilic S, Sonmez A, Yesilova Z, Uygun A, Gulsen M, Bagci S, Kemal Erbil M. Levels of soluble CD40 ligand and P-Selectin in nonalcoholic fatty liver disease. Dig Dis Sci 2010;55:1128-34. [PMID: 19440836 DOI: 10.1007/s10620-009-0817-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
33 de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol. 2014;88:548-559. [PMID: 24380887 DOI: 10.1016/j.bcp.2013.12.012] [Cited by in Crossref: 242] [Cited by in F6Publishing: 230] [Article Influence: 26.9] [Reference Citation Analysis]
34 Mindikoglu AL, Abdulsada MM, Jain A, Choi JM, Jalal PK, Devaraj S, Mezzari MP, Petrosino JF, Opekun AR, Jung SY. Intermittent fasting from dawn to sunset for 30 consecutive days is associated with anticancer proteomic signature and upregulates key regulatory proteins of glucose and lipid metabolism, circadian clock, DNA repair, cytoskeleton remodeling, immune system and cognitive function in healthy subjects. J Proteomics 2020;217:103645. [PMID: 31927066 DOI: 10.1016/j.jprot.2020.103645] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
35 Kilciler G, Genc H, Tapan S, Ors F, Kara M, Karadurmus N, Ercin CN, Karslioglu Y, Kilic S, Bagci S. Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease. Ups J Med Sci. 2010;115:253-259. [PMID: 20731535 DOI: 10.3109/03009734.2010.500062] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
36 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
37 Imarisio C, Alchera E, Sutti S, Valente G, Boccafoschi F, Albano E, Carini R. Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats. Clin Sci (Lond). 2012;123:323-332. [PMID: 22439844 DOI: 10.1042/cs20110504] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
38 Hong SP, Noh TS, Moon SH, Cho YS, Lee EJ, Choi JY, Kim BT, Lee KH. Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride. Dig Dis Sci 2014;59:607-13. [PMID: 24326630 DOI: 10.1007/s10620-013-2957-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
39 Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, Yu J, Teoh NC, Farrell GC. Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature: Systematic review of mouse NASH models. Journal of Gastroenterology and Hepatology 2018;33:1312-20. [DOI: 10.1111/jgh.14122] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
40 Tong M, Longato L, de la Monte SM. Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocr Disord 2010;10:4. [PMID: 20302640 DOI: 10.1186/1472-6823-10-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
41 Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA; American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011;123:1683-701. [PMID: 21403092 DOI: 10.1161/CIR.0b013e3182149099] [Cited by in Crossref: 209] [Cited by in F6Publishing: 79] [Article Influence: 19.0] [Reference Citation Analysis]
42 Van Camp JK, De Freitas F, Zegers D, Beckers S, Verhulst SL, Van Hoorenbeeck K, Massa G, Verrijken A, Desager KN, Van Gaal LF, Van Hul W. Investigation of common and rare genetic variation in the BAMBI genomic region in light of human obesity. Endocrine 2016;52:277-86. [PMID: 26499194 DOI: 10.1007/s12020-015-0778-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Sandhir R, Gupta S. Molecular and biochemical trajectories from diabetes to Alzheimer’s disease: A critical appraisal. World J Diabetes 2015; 6(12): 1223-1242 [PMID: 26464760 DOI: 10.4239/wjd.v6.i12.1223] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
44 Al-Dayyat HM, Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr 2018;12:569-75. [PMID: 29571977 DOI: 10.1016/j.dsx.2018.03.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
45 Shetty A, Hsu JW, Manka PP, Syn WK. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2018;63:3187-206. [PMID: 30121811 DOI: 10.1007/s10620-018-5242-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
46 Smith E, Tekola B, Patrie J, Cornella S, Caldwell S. Clinical Characterization of Gastric Antral Vascular Ectasia: A Potential Manifestation of the Metabolic Syndrome. Am J Med 2016; 129: 1329.e19-1329. e23. [PMID: 27476085 DOI: 10.1016/j.amjmed.2016.07.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 Zegers D, Verrijken A, Beckers S, Francque S, Van Camp JK, Aerts E, Ruppert M, Hubens G, Michielsen P, Van Hul W, Van Gaal LF. Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. Clin Res Hepatol Gastroenterol 2016;40:333-9. [PMID: 26500201 DOI: 10.1016/j.clinre.2015.09.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
48 Deibert P, Lazaro A, Schaffner D, Berg A, Koenig D, Kreisel W, Baumstark MW, Steinmann D, Buechert M, Lange T. Comprehensive lifestyle intervention vs soy protein-based meal regimen in non-alcoholic steatohepatitis. World J Gastroenterol 2019; 25(9): 1116-1131 [PMID: 30862999 DOI: 10.3748/wjg.v25.i9.1116] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. J Endocrinol 2015;227:179-91. [PMID: 26423094 DOI: 10.1530/JOE-15-0219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
50 Pagadala M, Dasarathy S, Eghtesad B, Mccullough AJ. Posttransplant metabolic syndrome: An epidemic waiting to happen: Posttransplant Metabolic Syndrome. Liver Transpl 2009;15:1662-70. [DOI: 10.1002/lt.21952] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 8.5] [Reference Citation Analysis]
51 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016;20:225-243. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
52 Moschen AR, Tilg H. Nutrition in pathophysiology and treatment of nonalcoholic fatty liver disease. Current Opinion in Clinical Nutrition & Metabolic Care 2008;11:620-5. [DOI: 10.1097/mco.0b013e32830b5d09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
53 Lo L, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, Gorrell MD, Yue DK, Twigg SM. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol. 2011;55:435-444. [PMID: 21184785 DOI: 10.1016/j.jhep.2010.10.039] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
54 Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int. 2019;13:674-687. [PMID: 31705444 DOI: 10.1007/s12072-019-09996-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
55 Renno A, Abdel-Aziz Y, Alastal Y, Khuder S, Hasan S, Assaly R, Nawras A. The association between obstructive sleep apnea and non-alcoholic steatohepatitis: a retrospective nationwide inpatient sample analysis. Clin Exp Hepatol 2021;7:25-9. [PMID: 34027112 DOI: 10.5114/ceh.2021.104488] [Reference Citation Analysis]
56 Lee SJ, Heinrich G, Fedorova L, Al-Share QY, Ledford KJ, Fernstrom MA, McInerney MF, Erickson SK, Gatto-Weis C, Najjar SM. Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice. Gastroenterology 2008;135:2084-95. [PMID: 18848945 DOI: 10.1053/j.gastro.2008.08.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
57 Shen H, Liu T, Zhang L, Zheng PY, Ji G, Xing LJ. Pathogenesis of increased sensitivity of hepatocytes to injury in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2010; 18(7): 685-688 [DOI: 10.11569/wcjd.v18.i7.685] [Reference Citation Analysis]
58 Kim Y, Lee H, Kim SY, Lim Y. Effects of Lespedeza Bicolor Extract on Regulation of AMPK Associated Hepatic Lipid Metabolism in Type 2 Diabetic Mice. Antioxidants (Basel) 2019;8:E599. [PMID: 31795363 DOI: 10.3390/antiox8120599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
59 Marchini JF, Souza FL, Schmidt A, Cunha SF, Salgado W Jr, Marchini JS, Nonino CB, Ceneviva R, Santos JE. Low educational status, smoking, and multidisciplinary team experience predict hospital length of stay after bariatric surgery. Nutr Metab Insights 2012;5:71-6. [PMID: 23882150 DOI: 10.4137/NMI.S10315] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Preuss HG, Kaats GR, Mrvichin N, Swaroop A, Bagchi D, Clouatre D, Preuss JM. Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects. J Am Coll Nutr 2018;37:457-65. [PMID: 29652564 DOI: 10.1080/07315724.2018.1443292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Zegers D, Verrijken A, Francque S, de Freitas F, Beckers S, Aerts E, Ruppert M, Hubens G, Michielsen P, Van Hul W, Van Gaal LF. Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. Clin Res Hepatol Gastroenterol 2016;40:715-21. [PMID: 27288299 DOI: 10.1016/j.clinre.2016.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Nakao H, Yoneda M. The intertwisted correlations among non-alcoholic fatty liver disease, atherosclerosis, and metabolic syndrome. J Gastroenterol 2009;44:1162-4. [DOI: 10.1007/s00535-009-0140-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
63 Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4:249-263. [PMID: 21765869 DOI: 10.1177/1756283x11403809] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
64 Bethel MA, Deedwania P, Levitt NS, Schmitz O, Huntsman-Labed A, Califf RM, Haffner SM, Diem P; NAVIGATOR Study Group. Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. Diabet Med 2009;26:1204-11. [PMID: 20002471 DOI: 10.1111/j.1464-5491.2009.02864.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
65 Ezquer M, Ezquer F, Ricca M, Allers C, Conget P. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome. J Hepatol 2011;55:1112-20. [PMID: 21356258 DOI: 10.1016/j.jhep.2011.02.020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
66 Jaruvongvanich V, Ahuja W, Wirunsawanya K, Wijarnpreecha K, Ungprasert P. Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:1031-1035. [PMID: 28639970 DOI: 10.1097/meg.0000000000000931] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
67 Wan Y, Garner J, Wu N, Phillip L, Han Y, McDaniel K, Annable T, Zhou T, Francis H, Glaser S, Huang Q, Alpini G, Meng F. Role of stem cells during diabetic liver injury. J Cell Mol Med 2016;20:195-203. [PMID: 26645107 DOI: 10.1111/jcmm.12723] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
68 Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:607-18. [PMID: 31695251 DOI: 10.1016/j.jceh.2018.10.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
69 Chung GE, Park HE, Kim MJ, Kwak MS, Yang JI, Chung SJ, Yim JY, Yoon JW. The Association between Low Muscle Mass and Hepatic Steatosis in Asymptomatic Population in Korea. Life (Basel) 2021;11:848. [PMID: 34440592 DOI: 10.3390/life11080848] [Reference Citation Analysis]
70 Han YM, Lee J, Choi JM, Kwak MS, Yang JI, Chung SJ, Yim JY, Chung GE. The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors. PLoS One 2021;16:e0260994. [PMID: 34898613 DOI: 10.1371/journal.pone.0260994] [Reference Citation Analysis]
71 Souza MRDA, Diniz MDFFDM, Medeiros-filho JEMD, Araújo MSTD. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89-96. [DOI: 10.1590/s0004-28032012000100015] [Cited by in Crossref: 102] [Cited by in F6Publishing: 72] [Article Influence: 10.2] [Reference Citation Analysis]
72 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
73 de la Monte SM, Tong M, Lawton M, Longato L. Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener 2009;4:54. [PMID: 20034403 DOI: 10.1186/1750-1326-4-54] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
74 Park HJ, Han JM, Kim HG, Choi MK, Lee JS, Lee HW, Son CG. Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. Hum Exp Toxicol 2013;32:1258-69. [PMID: 23970447 DOI: 10.1177/0960327113485253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
75 Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H, de la Monte SM. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis 2009;16:715-29. [PMID: 19387108 DOI: 10.3233/JAD-2009-0984] [Cited by in Crossref: 74] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
76 Mahran HN, Saber LM, Alghaithy AA, Elareefy AA. The role of elevated alanine aminotransferase (ALT), FasL and atherogenic dyslipidemia in type II diabetes mellitus. J Taibah Univ Med Sci 2017;12:8-13. [PMID: 31435207 DOI: 10.1016/j.jtumed.2016.10.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Pusl T, Wild N, Vennegeerts T, Wimmer R, Göke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun 2008;371:441-5. [PMID: 18452708 DOI: 10.1016/j.bbrc.2008.04.113] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
78 Caberlotto L, Nguyen TP, Lauria M, Priami C, Rimondini R, Maioli S, Cedazo-Minguez A, Sita G, Morroni F, Corsi M, Carboni L. Cross-disease analysis of Alzheimer's disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci Rep. 2019;9:3965. [PMID: 30850634 DOI: 10.1038/s41598-019-39828-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
79 Lee HJ, Ryu JM, Jung YH, Lee SJ, Kim JY, Lee SH, Hwang IK, Seong JK, Han HJ. High glucose upregulates BACE1-mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells. Sci Rep 2016;6:36746. [PMID: 27829662 DOI: 10.1038/srep36746] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
80 Abdalla MY, Mathahs MM, Ahmad IM. Reduced heme oxygenase-1 expression in steatotic livers infected with hepatitis C virus. Eur J Intern Med. 2012;23:649-655. [PMID: 22939811 DOI: 10.1016/j.ejim.2012.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
81 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2007;4:432-41. [DOI: 10.1038/ncpgasthep0879] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
82 de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:1582-605. [PMID: 22201977 DOI: 10.2741/482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 30] [Article Influence: 0.1] [Reference Citation Analysis]
83 Sahini N, Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res. 2014;54:86-112. [PMID: 24607340 DOI: 10.1016/j.plipres.2014.02.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
84 Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, Sun B, Li J, Flavell RA, Li HB, Ouyang X. m6A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep 2021;37:109968. [PMID: 34758326 DOI: 10.1016/j.celrep.2021.109968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Guo XY, Sun F, Chen JN, Wang YQ, Pan Q, Fan JG. circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling. World J Gastroenterol 2018; 24(3): 323-337 [PMID: 29391755 DOI: 10.3748/wjg.v24.i3.323] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
86 Bunchorntavakul C, Bahirwani R, Drazek D, Soulen MC, Siegelman ES, Furth EE, Olthoff K, Shaked A, Reddy KR. Clinical features and natural history of hepatocellular adenomas: the impact of obesity: Hepatocellular adenomas and obesity. Alimentary Pharmacology & Therapeutics 2011;34:664-74. [DOI: 10.1111/j.1365-2036.2011.04772.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]